Access all of the content
The VALOR-HCM trial showed the benefits of mavacamten as an alternative to surgical septal myectomy or alcohol ablation in patients with severely symptomatic obstructive hypertrophic cardiomyopathy. It was a pleasure to speak with Prof. Milind Desai (Cleveland Clinic, Cleveland, OH) about the VALOR-HCM trial including the efficacy and safety endpoints of it and what future studies of mavacamten are planned.
- Could you tell us a little about the VALOR-HCM trial? (00:21)
- What questions remain unanswered about the health benefits of mavacamten, and what future studies are planned? (04:45)
Disclosures: Milind Desai is a consultant for Bristol Myers Squibb and Medtronic.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Shanice Allen.
Filmed in coverage of the American College of Cardiology Annual Meeting 2022
Share this Video
Related Videos In Cardiovascular Disease
John Forrest, ACC 2023: Evolut low risk trial, transcatheter versus surgical aortic valve replacement in patients at low surgical risk
The Evolut low risk trial aimed to compare transcatheter versus surgical aortic valve replacement in patients who were at low risk for surgery. In this touchCARDIO interview, we speak with Dr John Forrest (Yale New Haven Hospital, Yale University, New Haven, CT, USA) to discuss the eligibility criteria, the key findings and the outlook for […]
John Forrest, ACC 2023: The treatment paradigm for patients with aortic stenosis
The treatment paradigm for aortic stenosis has developed dramatically in the past decade. In this touchCARDIO interview, we speak with Dr John Forrest (Yale New Haven Hospital, Yale University, New Haven, CT, USA) to outline and discuss the developments. Dr Forrest presented an abstract entitled ‘Transcatheter Versus Surgical Aortic Valve Replacement In Aortic Stenosis Patients […]
Steven Nissen, ACC 2023: Lipid-lowering therapies – current and future options
Many lipid-lowering therapies exist, such as statins to manage and reduce lipid levels. While statins are the most commonly used medication, some patients may need additional interventions to lower their LDL cholesterol levels. In this touchCARDIO interview, we speak with Prof. Steven Nissen (Cleveland Clinic, Cleveland, OH, USA) to explore current and developing novel lipid-lowering […]